


## Corrections

**PLANT BIOLOGY.** For the article “Identification of inhibitors of auxin transcriptional activation by means of chemical genetics in *Arabidopsis*,” by Joshua I. Armstrong, Shialou Yuan, Joseph M. Dale, Vanessa N. Tanner, and Athanasios Theologis, which appeared in issue 41, October 12, 2004, of *Proc. Natl. Acad. Sci. USA* (**101**, 14978–14983; first published October 4, 2004; 10.1073/pnas.0404312101), Fig. 1 contains an erroneous depiction of compound **D**. This problem appears to be a result of an internal database error early in our studies that propagated the incorrect structure throughout our figure preparation process. This correction does not affect the conclusions of the article. The corrected figure and its legend appear below.



**Fig. 1.** A high-throughput screen for auxin signaling inhibitors. (A) BA3 seeds expressing GUS from an auxin-sensitive promoter were arrayed into 96-well microfilter plates (5–10 seeds per well) and grown in liquid culture for 5 days. Incubation of the seedlings with 5  $\mu$ M NAA results in the tissue-specific expression of GUS in the root elongation zone, easily visualized after incubation with 5-bromo-4-chloro-3-indolyl  $\beta$ -D-glucuronide (X-gluc). The inclusion of an inhibitor of auxin signaling prevents GUS expression. (B) Structures of the four inhibitors, compounds **A–D**, chosen for detailed analysis.

**MEDICAL SCIENCES.** For the article “Large-scale cDNA transfection screening for genes related to cancer development and progression,” by Dafang Wan, Yi Gong, Wenxin Qin, Pingping Zhang, Jinjun Li, Lin Wei, Xiaomei Zhou, Hongnian Li, Xiaokun Qiu, Fei Zhong, Liping He, Jian Yu, Genfu Yao, Huiqiu Jiang, Lianfang Qian, Ye Yu, Huiqun Shu, Xianlian Chen, Huili Xu, Minglei Guo, Zhimei Pan, Yan Chen, Chao Ge, Shengli Yang, and Jianren Gu, which appeared in issue 44, November 2, 2004, of *Proc. Natl. Acad. Sci. USA* (**101**, 15724–15729; first published October 21, 2004; 10.1073/pnas.0404089101), the authors note that on page 15725, in paragraphs 2 and 3 under the subheading *Measurement of Colony Formation of SMMC7721 Cells and Focus Formation of NIH 3T3 Cells*, “JCL-1/breast-cancer-associated gene” incorrectly appeared as “JCL-1/bacillus Calmette–Guérin 1.”

www.pnas.org/cgi/doi/10.1073/pnas.0408124101

**MEDICAL SCIENCES.** For the article “Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon  $\beta$ ,” by Bibiana Bielekova, Nancy Richert, Thomas Howard, Gregg Blevins, Silva Markovic-Plese, Jennifer McCartin, Jens Würfel, Joan Ohayon, Thomas A. Waldmann, Henry F. McFarland, and Roland Martin, which appeared in issue 23, June 8, 2004, of *Proc. Natl. Acad. Sci. USA* (**101**, 8705–8708; first published May 25, 2004; 10.1073/pnas.0402653101), the authors request that Joseph A. Frank, Experimental Neuroimaging Section, Laboratory of Diagnostic Radiology Research, National Institutes of Health, Bethesda, MD 20892-1074, be added to the author list between Jennifer McCartin and Jens Würfel. The online version has been corrected. The corrected author and affiliation lines appear below.

**Bibiana Bielekova\***, **Nancy Richert\***, **Thomas Howard\***, **Gregg Blevins\***, **Silva Markovic-Plese\*†**, **Jennifer McCartin\***, **Joseph A. Frank‡**, **Jens Würfel\*§**, **Joan Ohayon\***, **Thomas A. Waldmann¶**, **Henry F. McFarland\***, and **Roland Martin¶||**

\*Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892;

†Department of Neurology, University of North Carolina at Chapel Hill, 6109 Neuroscience Research Building, Chapel Hill, NC 27599; ‡Experimental Neuroimaging Section, Laboratory of Diagnostic Radiology Research, National Institutes of Health, Bethesda, MD 20892-1074; §Institute of Neuroimmunology, Charité, Humboldt-University Berlin, Schumannstrasse 20/21, D-10117 Berlin, Germany; and ¶Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892

||To whom correspondence should be addressed at: Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, 10 Center Drive, MSC 1400, Bethesda, MD 20892. E-mail: martin@ninds.nih.gov.

www.pnas.org/cgi/doi/10.1073/pnas.0404694101

www.pnas.org/cgi/doi/10.1073/pnas.0408339101

www.pnas.org

PNAS | December 14, 2004 | vol. 101 | no. 50 | 17565

www.manaraa.com